(Originally published on Nov 12, 2020) To win the battle with SARS-CoV-2 ENDECE a revolutionary biotech company based in Portland, OR. has developed a biotherapeutic designed to regain control of immune response preventing ARDS (Acute Respiratory Distress Syndrome)....
As SARS-Cov-2 / COVID-19 continues to dominate our lives, the world is looking for a way to get back to “Normal”. Unfortunately, “Normal”, is a long ways off and may have to be redefined in general. Public health officials are confident that broad vaccination will...
We need both vaccines and therapeutics as not everyone will be immunized effectively against SARS-CoV-2 / COVID-19 The search for a SARS-CoV-2 vaccine continues to be of high priority. However, there are several aspects of SARS-CoV-2 and other viruses, such as the...
Within the US alone, there are over 200,000 hospitalizations annually from seasonal viral influenza. Patients requiring mechanical ventilation have a high mortality rate of 20% or over 40,000 people annually.The World Health Organization (WHO) estimates that influenza...
The differences between NDC-1308 (MC1) and Dexamethasone proposed Mechanism of Action (MOA) support NDC-1308 (MC1) may have increased efficacy compared to Dexamethasone in all COVID-19 patient groups. By addressing the early signs of lung inflammation in COVID-19...
WHAT IS A MACROPHAGE? A macrophage is a type of white blood cell called a phagocyte. It is the first line of defense that cleans the body of bacteria and viruses called antigens. When a macrophage locates an antigen, it engulfs and destroys it. Upon being presented...
